MASSACHUSETTS GENERAL HOSPITAL

Novo Nordisk shares fell 6% after mixed Phase 2 weight-loss drug results; Sanofi presented data supporting tolebrutinib for MS; Lasker Awards given to scientists for GLP-1 weight-loss drug research; Edgewise Therapeutics' heart failure drug shows promising early results; FDA declines to approve Vanda Pharmaceuticals' gastroparesis drug; House Energy and Commerce Committee supports extending pediatric rare disease voucher program.

Black women face higher breast cancer mortality across all tumor subtypes, with risks varying from 17% to 50% higher. Factors beyond tumor biology, including socioeconomic inequality and limited access to quality treatment, contribute to these disparities. Comprehensive interventions are needed to address these inequities.

Tampa General Hospital (TGH) and Mass General Brigham (MGB) expand their affiliation with new programs, including a bone marrow transplant and CAR-T therapy program. They also grow healthcare services for Florida's veterans through Home Base Florida. The collaboration aims to enhance patient care and medical innovation in Florida.

MDA awards $500,000 to MGH's HEALEY ALS Platform Trial, led by Dr. Sabrina Paganoni, to accelerate ALS treatment research.

Svetlana Mojsov, recipient of the 2024 Lasker~DeBakey Clinical Medical Research Award, discovered GLP-1, pivotal in insulin secretion and blood glucose regulation, leading to revolutionary diabetes, obesity, and cardiovascular disease treatments. Mojsov, along with Joel F. Habener and Lotte Bjerre Knudsen, will be honored at a September 27 ceremony in New York City.

Pomalidomide, approved for multiple myeloma, significantly reduces severe nosebleeds in HHT patients, improving quality of life, according to the PATH-HHT study published in the New England Journal of Medicine.

Tampa General Hospital to expand services with Mass General Brigham, including new cancer treatments, bone marrow transplants, and enhanced mental health care for veterans via the Home Base Florida program.

Black women have a 17% to 50% higher risk of dying from any type of breast cancer compared to white women, according to a review of 18 studies. This disparity exists across all breast cancer subtypes and is partly due to systemic racism and socioeconomic factors.

A meta-analysis by Mass General Brigham researchers reveals Black women have a higher risk of dying from all breast cancer subtypes, with disparities ranging from 17-50%. These disparities are attributed to socioeconomic inequality, delays in diagnosis, and inadequate access to treatment, independent of tumor biology. Interventions at multiple levels are necessary to achieve equity in breast cancer outcomes.

Tampa General Hospital and Mass General Brigham deepen affiliation, introducing new programs like bone marrow transplant and CAR-T therapy, and expanding services for Florida veterans through Home Base Florida, marking three years of collaboration focused on medical innovation, research, and patient care.